Biopharma company deals with nonprofit entities, as well as grants, are not keeping the same pace as last year, but the proportion of money flowing into COVID-19 efforts continues to account for the majority of those recorded overall.
The completion of the third largest biopharmaceutical acquisition on record has significantly boosted M&A values in 2021, although the industry still falls more than 38% below the same period last year.
Bioworld’s Drug Developers Index is at its highest point this year, up 4.99%, despite some index members receiving FDA complete response letters and reporting lower-than-expected sales within the last month. Moderna Inc., with its mRNA-1273 COVID-19 vaccine gaining more traction worldwide, is largely responsible for the rise, with its own shares (NASDAQ:MRNA) up nearly 285%.
RSS
